Details of the Researcher

PHOTO

Yumi Kambayashi
Section
Tohoku University Hospital
Job title
Assistant Professor
Degree

  • 博士（医学）（東北大学）

e-Rad No.
50755303

Education 2

  • 東北大学大学院　医学部　医学系研究科

    2011/04 - 2015/03

  • Tokyo Women's Medical University　Faculty of Medicine

    2000/04 - 2006/03

Research Areas 1

  • Other / Other /

Awards 1

  1. 東北大学大学院医学系研究科女子大学院学生奨励賞（七星賞）

    2016

Papers 140

  1. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoru Mizuhashi, Takamichi Ito, Takeo Maekawa, Shoichiro Ishizuki, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Koji Yoshino, Yasuhiro Fujisawa, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Satoshi Fukushima, Yoshihide Asano, Taku Fujimura

    Cancers　16　(15)　2024/08/02

    DOI： 10.3390/cancers16152755 　

    More details Close

    BACKGROUND: Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. However, the long-term efficacy of this therapy on the melanoma acral and mucosal subtypes has not been fully evaluated in previous trials. This study assessed the 3-year recurrence-free survival and overall survival of patients with melanoma, including the acral and mucosal subtypes, treated with anti-PD-1 antibody (Ab) or with the combination of the BRAF and MEK inhibitors dabrafenib and trametinib. METHODS: We retrospectively analyzed both the 3-year time to relapse (TTR) and overall survival (OS) of 120 patients treated with anti-PD-1 antibody (Ab), or with the combination of dabrafenib and trametinib. RESULTS: The overall median TTR was 18.4 months, with a range of 0.69 to 36 months. The 3-year TTR of the acral and mucosal types was 28.1% and 38.5%, respectively. Baseline tumor thickness (TT) and acral type were associated with the TTR in subgroup analysis. Moreover, we classified 104 acral and non-acral cutaneous patients into the anti-PD-1 Abs or dabrafenib plus trametinib combined therapies cohort in multiple analyses. The acral subtype and TT were detected as important prognostic factors. In the 3-year OS, only tumor ulceration was associated with the OS in both univariate and multiple analyses. There was no significant difference in baseline or treatment-related factors of the mucosal type (p > 0.05). CONCLUSION: This study suggests that adjuvant therapy is more effective with non-acral cutaneous melanoma than either the acral or mucosal types at the 3-year TTR endpoint.

  2. Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial. International-journal

    Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Shoichiro Ishizuki, Atsushi Otsuka, Shigeto Matsushita, Ryo Amagai, Yusuke Muto, Emi Yamazaki, Yumi Kambayashi, Takashi Yahata, Toshio Miyata, Yasuhiro Fujisawa, Yoshihide Asano

    The British journal of dermatology　2024/06/04

    DOI： 10.1093/bjd/ljae231 　

    More details Close

    BACKGROUND: Anti-programmed cell death 1 antibodies (anti-PD-1 Abs) are widely used for advanced melanoma, but the efficacy of an anti-PD-1 Abs is limited in the Asian population. There remains an unmet need to improve the therapeutic effects of anti-PD-1 Abs treatment, particularly in melanoma patients who are refractory to anti-PD-1 Abs. The aim was to evaluate anti-PD-1 Abs treatment in combination with TM5614 (plasminogen activator inhibitor-1: PAI-1 inhibitor) in patients with unresectable melanoma. METHODS: The TM5614-MM study was a multicentre, open-label, single-arm, phase 2 clinical trial to evaluate the efficacy and safety of nivolumab in combination with TM5614 in patients with advanced, unresectable malignant melanoma recruited at 7 Japanese institutes between 13 September 2021 and 31 March 2023. Patients with metastatic or unresectable melanoma previously treated with anti-PD-1 Abs were enrolled. Nivolumab 480 mg was administered intravenously every 4 weeks for 8 weeks, while TM5614 was administered orally at a dose of 120 mg (0-4 weeks) and 180 mg once daily (5-8 weeks). The primary endpoint was the overall response rate after 8 weeks of concomitant use of TM5614. RESULTS: Thirty nine patients were enrolled, and 34 patients in the anti-PD-1 Abs-refractory cohort. The overall response rate at 8 weeks was 25.9% (95% CI: 12.9-44.9%; P = .027) in 27 anti-PD-1-Abs refractory patients by investigator assessment in the protocol per set cohort. Seven patients discontinued treatment due to progressive disease or adverse events. Treatment-related grade 3 or higher adverse events occurred in 3 of 39 patients (7.7%) in the intention-to-treat cohort. CONCLUSIONS: TM5614 in combination with nivolumab is well-tolerated and effective in anti-PD-1 Abs-refractory, unresectable melanoma. TRIAL REGISTRATION: This trial was registered with Clinical Trial gov, jRCT2021210029.

  3. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol. International-journal

    Taku Fujimura, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Akira Hashimoto, Yumi Kambayashi, Naoya Yamazaki, Toshio Miyata, Yoshihide Asano

    Experimental dermatology　2023/11/09

    DOI： 10.1111/exd.14976 　

    More details Close

    Cutaneous angiosarcoma (CAS) is an endothelial cell-derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial, and there is no standard therapy for taxane-resistant CAS. Plasminogen activator inhibitor-1 (PAI-1) is associated with poor clinical outcomes, and elevated levels of PAI-1 in both tissue and serum are correlated with poor response to therapy in various cancers, including skin cancers. Since PAI-1 protects endothelial cells from Fas ligand-mediated apoptosis, PAI-1 inhibition might induce apoptosis of endothelial cell-derived tumours such as CAS. This is a single-arm, open-label, multi-institutional, Phase 2 clinical trial to assess the efficacy and safety of PTX in combination with TM5614 (PAI-1 inhibitor) in patients with PTX-resistant CAS. PTX will be administered for 28 weeks, with oral administration of TM5614. The primary endpoint of this study will be the overall response rate (ORR) at 28 weeks after starting treatment (central image evaluation). The secondary endpoint will include the ORR at 28 weeks after starting treatment (investigator evaluation), ORR at 8 weeks and 16 weeks after initiation of treatment (central and investigator evaluation), progression-free survival, overall survival, disease control rate and safety profiles. Assuming the null hypothesis of a response rate of 13.6% and an alternative hypothesis of 45%, a minimum of 15 patients are required to achieve a two-sided, Type I error of 5% and power of 70% based on the exact binomial distribution. Data quality control will be conducted by a combination of centralized (remote) and on-site monitoring. This study will contribute to the development of novel combination therapy for PTX-resistant CAS patients, which remains an unmet clinical need.

  4. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    The Journal of dermatology　2023/07/30

    DOI： 10.1111/1346-8138.16912 　

    More details Close

    Since anti-PD-1 Abs can cause irreversible immune-related adverse events (irAEs), the associations between their efficacies and the incidence of irAEs are important to evaluate the use of anti-PD-1Abs for the treatment of melanoma, especially in the adjuvant setting. The purpose of this post hoc analysis study was to retrospectively analyze the associations between recurrence-free survival (RFS) at 12 months and the onset of any irAEs in 31 non-acral cutaneous and 30 acral melanoma cases treated with anti-PD-1 Abs therapy at the adjuvant setting in Asians. There were 20 cases with greater than grade 1 AEs in both the acral and non-acral cutaneous groups. Of the acral melanoma, 10 cases were nails or toes, and 20 cases were soles and heels. The log-rank test showed that RFS was better in cases with AEs than in cases without AEs. The present study suggested that the different profiles of irAEs between non-acral cutaneous and acral melanoma might correlate with the different response to anti-PD1 Abs of melanoma in the adjuvant setting.

  5. Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Ishizuki Shoichiro, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Koji Yoshino, Yasuhiro Fujisawa, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    The British journal of dermatology　2023/05/27

    DOI： 10.1093/bjd/ljad183 　

  6. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. International-journal

    Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, Akira Hashimoto, Yumi Kambayashi, Yoshihide Asano

    The Journal of dermatology　2023/03/20

    DOI： 10.1111/1346-8138.16786 　

    More details Close

    Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane-switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.

  7. Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Taku Fujimura

    Acta dermato-venereologica　102　adv00756　2022/08/11

    DOI： 10.2340/actadv.v102.678 　

    More details Close

    Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2-70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6-50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types.

  8. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. International-journal

    Yumi Kambayashi, Yuki Kasahara, Kentaro Ohuchi, Ryo Amagai, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    Dermatologic therapy　35　(10)　e15736　2022/07/27

    DOI： 10.1111/dth.15736 　

    More details Close

    Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. A small subpopulation of DFSP undergoes fibrosarcomatous (FS) change, and approximately 15%-57% of cases of DFSP with FS change metastasizes, leading to a poor prognosis. In this report, a case of metastatic FS-DFSP that was successfully treated with imatinib mesylate in which the IHC staining pattern of recurrent DFSP was quantitatively analyzed in primary and metastatic DFSP areas, is described. Importantly, the recurrent area was composed of two IHC staining patterns (CD34low PD-L1high Ki67high , and CD34high PD-L1low Ki67low pattern), while the metastatic area showed a clonal pattern (CD34high PD-L1low Ki67intermediate ) in the present case. In this report, we described a case of metastatic fibrosarcomatous DFSP successfully treated with imatinib mesylate. This case suggests a subpopulation of DFSP with a favorable metastatic pattern.

  9. 進行期メラノーマに対するニボルマブ・PAI-1阻害薬併用療法の安全性・有効性の検討

    藤村 卓, 吉野 公二, 加藤 裕史, 福島 聡, 大塚 篤司, 松下 茂人, 神林 由美, 橋本 彰, 藤澤 康弘

    日本皮膚科学会雑誌　132　(5)　1314-1314　2022/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  10. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. International-journal

    Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Yumi Kambayashi, Taku Fujimura

    The Journal of dermatology　49　(5)　e167-e168　2022/05

    DOI： 10.1111/1346-8138.16304 　

  11. Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report. International-journal

    Mayuko Amagai, Maki Ozawa, Ryo Amagai, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Setsuya Aiba, Taku Fujimura

    Dermatologic therapy　35　(3)　e15290　2022/03

    DOI： 10.1111/dth.15290 　

  12. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases

    Taku Fujimura, Sadanori Furudate, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Akira Hashimoto, Yusuke Muto, Kentaro Ohuchi, Ryo Amagai, Yumi Kambayashi, Yasuhiro Fujisawa

    Skin Health and Disease　2022

    DOI： 10.1002/ski2.180 　

    eISSN： 2690-442X

  13. 進行期悪性黒色腫に対するダブラフェニブ・トラメチニブ術後補助療法 多施設共同後ろ向き研究

    藤村 卓, 武藤 雄介, 神林 由美, 加藤 裕史, 松下 茂人, 前川 武雄, 福島 聡, 吉野 公二, 内 博史, 藤澤 康弘

    日本皮膚科学会雑誌　132　(1)　86-86　2022/01

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  14. Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases. International-journal

    Ryo Amagai, Yusuke Muto, Hiroshi Kato, Shigeto Matsushita, Takeo Maekawa, Satoshi Fukushima, Koji Yoshino, Hiroshi Uchi, Yasuhiro Fujisawa, Yuki Yamamoto, Kentaro Ohuchi, Yumi Kambayashi, Taku Fujimura

    Melanoma research　31　(6)　575-578　2021/12/01

    DOI： 10.1097/CMR.0000000000000770 　

    More details Close

    Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab) therapy reduce the risk of recurrence in patients with resected stage III BRAF-mutated melanoma, selecting the adjuvant therapy for BRAF-mutated melanoma is controversial. The efficacy and safety profiles of D+T combined therapy in the adjuvant setting were retrospectively analyzed in 36 Japanese. BRAF-mutated advanced melanoma patients. The relapse-free rate (RFR) at 12 months was 82.1% (95% confidential interval (CI), 63.9-92.6%). In the 21 patients who completed the protocol, the RFR at 12 months was 85.7% (95% CI, 64.5-95.9%). In the seven patients whose protocol was interrupted by adverse events, the RFR was 71.4% (95% CI, 35.2-92.4%). The incidence rate of any AEs for all patients was 69.7% (95% CI, 52.5-82.8%), including 13 cases of pyrexia, five cases of skin rash and four cases of liver dysfunction. The present study suggested that D+T therapy in the adjuvant setting is a useful and very tolerable protocol for BRAF-mutated melanoma in the Japanese population.

  15. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy. International-journal

    Takami Okuma, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba, Taku Fujimura

    The Journal of dermatology　48　(9)　1419-1422　2021/05/18

    DOI： 10.1111/1346-8138.15962 　

    More details Close

    BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapeutic regimens for the treatment of advanced BRAF-mutant melanoma. Although the NCCN guideline for cutaneous melanoma recommended BRAF/MEK inhibitors as first-line therapies for unresectable BRAF-mutated melanoma, resistance to these drugs should be taken into account in real-world practice. Therefore, development of a protocol for BRAF/MEK inhibitor-resistant advanced melanoma is needed. In this report, a case of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma that was successfully treated with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy (IMRT) is reported. In the present case, not only the locally irradiated lesion, but remote metastases including inguinal lymph nodes decreased after ipilimumab plus nivolumab followed by IMRT treatment leading to complete remission, suggesting that IMRT triggered an abscopal response. Moreover, immunohistochemical analysis showed increased CD3+ , CD4+ , and CD8+ T cells after radio-immunotherapy (RIT). This case suggests that RIT might break the tolerance in the tumor microenvironment and induce a systemic anti-melanoma immune response.

  16. 当科におけるメラノーマに対する術後補助療法の後方視的検討

    武藤 雄介, 藤村 卓, 神林 由美, 古舘 禎騎, 大内 謙太郎, 天貝 諒, 千葉 広夢, 大熊 崇生, 相場 節也

    日本皮膚科学会雑誌　131　(5)　1416-1416　2021/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  17. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. International-journal

    Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　48　(3)　397-400　2021/03

    DOI： 10.1111/1346-8138.15688 　

    More details Close

    The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.

  18. Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma. International-journal

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　48　(3)　e135-e136　2021/03

    DOI： 10.1111/1346-8138.15747 　

  19. Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas. International-journal

    Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Setsuya Aiba

    Pharmaceutics　13　(2)　2021/02/02

    DOI： 10.3390/pharmaceutics13020200 　

    More details Close

    Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

  20. Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients. International-journal

    Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, Taku Fujimura

    Frontiers in oncology　11　798385-798385　2021

    DOI： 10.3389/fonc.2021.798385 　

    More details Close

    Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1 expression on melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1 antibodies (Abs). These findings suggested that PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of PAI-1 in melanoma patients were evaluated, and the immunomodulatory effects of PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of PAI-1 showed that PAI-1 expression on melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of PAI-1 were significantly decreased in responders compared to non-responders. Notably, PAI-1 decreased the production of various chemokines from monocyte-derived M2 macrophages in vitro, suggesting that PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of PAI-1 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  21. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. International-journal

    Ryo Amagai, Taku Fujimura, Yusuke Muto, Yumi Kambayashi, Sadanori Furudate, Kentaro Ohuchi, Takami Okuma, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　34　(1)　e14544　2021/01

    DOI： 10.1111/dth.14544 　

    More details Close

    Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon-inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune-related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs.

  22. Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma. International-journal

    Taku Fujimura, Kayo Tanita, Kentaro Ohuchi, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Yasuhiro Fujisawa, Ryota Tanaka, Akira Hashimoto, Setsuya Aiba

    Melanoma research　30　(6)　613-618　2020/12

    DOI： 10.1097/CMR.0000000000000685 　

    More details Close

    Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma. However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  23. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. International-journal

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　33　(6)　e14430　2020/11

    DOI： 10.1111/dth.14430 　

  24. Treatment of Advanced Melanoma: Past, Present and Future. International-journal

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba

    Life (Basel, Switzerland)　10　(9)　2020/09/16

    DOI： 10.3390/life10090208 　

    More details Close

    Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

  25. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment. International-journal

    Kentaro Ohuchi, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Chunbing Lyu, Kayo Tanita, Yota Sato, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13487　2020/07

    DOI： 10.1111/dth.13487 　

    More details Close

    Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) in advanced cutaneous T-cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for the treatment of advanced CTCL, its efficacy is unsatisfactory, especially in mycosis fungoides (MF). Therefore, additional drugs to enhance the antitumor effects of mogamulizumab are needed to further optimize its use for the treatment of MF. In this report, two cases of mogamulizumab-resistant MF successfully treated with additional administration of etoposide are presented. Moreover, the possible mechanisms of mogamulizumab-etoposide combined therapy for the treatment of MF were investigated based on the modulation of chemokine profiles in vivo using an EL-4 mouse T-cell lymphoma model. Intraperitoneal administration of etoposide significantly increased the mRNA expressions of CCL17, CXCL5, and CXCL10, suggesting that CCR4+ CTCL cells gather around the tumor-associated macrophagess. Furthermore, the immunomodulatory effects of etoposide on the mRNA expressions of these chemokines were validated using monocyte-derived M2 macrophages in vitro. Since mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by ADCC that depends on the contact between the lymphoma cells and the effector cells, these chemokines could enhance the therapeutic effect of mogamulizumab.

  26. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy. International-journal

    Taku Fujimura, Yumi Kambayashi, Hisayuki Tono, Chinbing Lyu, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13672　2020/07

    DOI： 10.1111/dth.13672 　

    More details Close

    Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.

  27. Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy. International-journal

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13731　2020/07

    DOI： 10.1111/dth.13731 　

  28. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. International-journal

    Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　47　(6)　654-657　2020/06

    DOI： 10.1111/1346-8138.15346 　

    More details Close

    Various serious adverse events (AE) have been reported to occur at a high rate in patients treated with BRAF plus mitogen-activated protein kinase kinase (MEK) inhibitor combination therapy, but their subtypes differ among the BRAF/MEK inhibitors. Pyrexia or a spike of fever are well-known AE of BRAF inhibitors, with or without MEK inhibitors, and have been reported to have a high incidence after dabrafenib/trametinib, but not after encorafenib/binimetinib. In this report, we describe three cases of severe pyrexia in nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. Interestingly, in all cases, the serum levels of soluble CD163 C-X-C motif chemokine (CXCL)9, CXCL10 and CXCL11, which are known biomarkers for adult-onset Still's disease (AOSD), increased in parallel with the development of pyrexia. Our present cases suggest that pyrexia caused by BRAF/MEK inhibitors may possess a similar pathophysiology as that of AOSD.

  29. Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy

    Yumi Kambayashi, Taku Fujimura, Hiroshi Kuroda, Atsushi Otsuka, Hiroyuki Irie, Setsuya Aiba

    Case Reports in Oncology　13　(1)　474-477　2020/04/30

    Publisher: S. Karger AG

    DOI： 10.1159/000506976 　

    eISSN： 1662-6575

  30. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. International-journal Peer-reviewed

    Taku Fujimura, Yota Sato, Kayo Tanita, Ryo Amagai, Takatoshi Shimauchi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Yasuhiro Fujisawa, Yumi Kambayashi, Setsuya Aiba

    The Journal of dermatology　2020/03/24

    DOI： 10.1111/1346-8138.15322 　

    More details Close

    Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world. However, continuous administration of bexarotene is sometimes difficult because of its adverse events (AE). Development of an appropriate protocol for bexarotene that can induce a consistent response for CTCL without severe AE (SAE) is needed. We retrospectively investigated 29 Japanese cases of CTCL and evaluated the efficacy of treatment and incident ratios of all AE and SAE. Objective response rate (ORR) for the overall cohort was 65.5%. ORR of the 300 mg/m2 cohort (conventional dose) was 76.2%, while that of the 150-300 mg/body (low dose) with narrowband ultraviolet B light (NBUVB) cohort was 37.5%. Mean event-free survival was 10.0 months for all patients, 6.7 months for the bexarotene conventional-dose cohort and 19.1 months for the low-dose with NBUVB cohort. The incident ratio of total SAE for all patients was 20.7%. The incident ratio of total SAE was 23.8% for the conventional-dose cohort and 12.5% for the low-dose with NBUVB cohort. Our present study suggests that low-dose bexarotene plus NBUVB therapy is well-tolerated and could be one of the optimal therapies for advanced CTCL.

  31. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. International-journal Peer-reviewed

    Dai Ogata, Kenjiro Namikawa, Masaki Otsuka, Jun Asai, Hisoshi Kato, Masahito Yasuda, Takeo Maekawa, Taku Fujimura, Junji Kato, Tatsuya Takenouchi, Kotaro Nagase, Masakazu Kawaguchi, Tatsuya Kaji, Yutaka Kuwatsuka, Yoshitsugu Shibayama, Toshihiro Takai, Mao Okumura, Yumi Kambayashi, Syusuke Yoshikawa, Naoya Yamazaki, Tetsuya Tsuchida

    European journal of cancer (Oxford, England : 1990)　127　108-117　2020/03

    DOI： 10.1016/j.ejca.2019.12.018 　

    More details Close

    BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited. Therefore, we aimed to determine the most effective systemic treatment for acSCC. PATIENTS AND METHODS: This retrospective study involved 16 Japanese institutions. We documented patient and tumour characteristics and disease course of patients with acSCC who received systemic therapy between 1st January 2006 and 31st December 2015. We compared the overall survival (OS) and progression-free survival (PFS) for (1) platinum versus non-platinum groups, (2) radiation plus chemotherapy first-line therapy (RCT) versus non-RCT groups and (3) platinum-based RCT versus non-platinum-based RCT groups. RESULTS: Although the use of platinum-based systemic therapy was not associated with statistically significant improvements in PFS and OS, there were significant differences between the RCT and non-RCT groups (PFS: p < 0.001, OS: p = 0.003). In the subgroup analysis, RCT significantly prolonged PFS and OS in the nodal SCC (nSCC) group. For the RCT and non-RCT groups, the median OS was 110 and 14 months, respectively, and the 5-year OS rate was 54% and 21%, respectively. CONCLUSION: RCT could improve OS in patients with nSCC. However, further multicenter prospective studies are needed to establish evidence for superiority of RCT.

  32. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study Peer-reviewed

    Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, Kambayashi Y, Aoki M, Yanagi T, Ohira A, Nakamura Y, Maeda T, Yoshino K

    British Journal of Dermatology　2020/03

  33. Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　1141-1144　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000510261 　

    ISSN： 1662-6575

  34. IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

    Saaya Yoshida, Taku Fujimura, Kentaro Ohuchi, Yumi Kambayashi, Yuichiro Segawa, Emi Yamazaki, Hisayuki Tono, Toshiya Takahashi, Kenichiro Tsuchiyama, Setsuya Aiba

    Case Reports in Oncology　13　(1)　462-467　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000506975 　

    ISSN： 1662-6575

  35. Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　13　(1)　271-275　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000506327 　

    ISSN： 1662-6575

  36. First-in-human clinical study of novel technique to diagnose malignant melanoma via thermal conductivity measurements Peer-reviewed

    Takahiro Okabe, Taku Fujimura, Junnosuke Okajima, Yumi Kambayashi, Setsuya Aiba, Shigenao Maruyama

    Scientific Reports　9　(1)　3853　2019/12/01

    DOI： 10.1038/s41598-019-40444-6 　

    eISSN： 2045-2322

  37. Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy. Peer-reviewed

    Yoshida S, Fujimura T, Kambayashi Y, Amagai R, Hashimoto A, Aiba S

    Case reports in oncology　12　(3)　829-833　2019/09

    DOI： 10.1159/000504019 　

  38. Advanced Invasive Extramammary Paget's Disease Concomitant with Cecal Cancer Possessing Rare Variant of TP53 Single Nucleotide Polymorphism. Peer-reviewed

    Kambayashi Y, Fujimura T, Ohuchi K, Tono H, Ishida Y, Otsuka A, Aiba S

    Case reports in oncology　12　(3)　855-860　2019/09

    DOI： 10.1159/000504339 　

  39. A novel technique to diagnose non-melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors. Peer-reviewed

    Fujimura T, Okabe T, Tanita K, Sato Y, Lyu C, Kambayashi Y, Maruyama S, Aiba S

    Experimental dermatology　28　(9)　1029-1035　2019/09

    DOI： 10.1111/exd.13997 　

    ISSN： 0906-6705

  40. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. International-journal Peer-reviewed

    Fujimura T, Fujisawa Y, Kambayashi Y, Aiba S

    Cancers　11　(9)　2019/09

    DOI： 10.3390/cancers11091342 　

    More details Close

    According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. In addition, drug resistance sometimes abrogates the persistent efficacy of combined therapy with BRAF and MEK inhibitors. Therefore, recent pre-clinical study-based clinical trials have attempted to identify optimal drugs (e.g., immune checkpoint inhibitors or histone deacetylase (HDAC) inhibitors) that improve the anti-melanoma effects of BRAF and MEK inhibitors. In addition, the development of novel protocols to avoid resistance of BRAF inhibitors is another purpose of recent pre-clinical and early clinical trials. This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.

  41. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. Peer-reviewed

    Irimada M, Fujimura T, Kambayashi Y, Tsukada A, Takahashi T, Hashimoto A, Aiba S

    The Journal of dermatology　46　(7)　e256-e258　2019/07

    DOI： 10.1111/1346-8138.14778 　

    ISSN： 0385-2407

  42. Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. Peer-reviewed

    Fujimura T, Kambayashi Y, Sato Y, Tanita K, Tono H, Lyu C, Takahashi T, Hashimoto A, Aiba S

    The Journal of dermatology　46　(7)　e260　2019/07

    DOI： 10.1111/1346-8138.14786 　

    ISSN： 0385-2407

  43. 衛星病巣を伴った色素性母斑の2例

    山崎 絵美, 菊地 克子, 中嶋 夏磯, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚科学会雑誌　129　(7)　1505-1510　2019/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  44. 多巣性線維硬化症の1例

    瀬川 倫子, 水芦 政人, 志藤 光介, 玉渕 恵里佳, 神林 由美, 相場 節也, 城田 祐子

    日本皮膚科学会雑誌　129　(5)　1169-1169　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  45. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy. Peer-reviewed

    Amagai R, Fujimura T, Kambayashi Y, Sato Y, Tanita K, Hashimoto A, Aiba S

    The Journal of dermatology　46　(5)　449-452　2019/05

    DOI： 10.1111/1346-8138.14861 　

    ISSN： 0385-2407

  46. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Peer-reviewed

    Fujimura T, Hidaka T, Kambayashi Y, Aiba S

    Expert opinion on investigational drugs　28　(2)　143-148　2019/02

    DOI： 10.1080/13543784.2019.1558442 　

    ISSN： 1354-3784

  47. Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma. International-journal Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Hideki Nakajima, Motoki Nakamura, Akimichi Morita, Setsuya Aiba

    Frontiers in oncology　9　907-907　2019

    DOI： 10.3389/fonc.2019.00907 　

    More details Close

    Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of both early and advanced cutaneous T-cell lymphoma (CTCL). Although bexarotene has been used for decades in the treatment of CTCL, little is known about the mechanisms underlying its anti-tumor effects in CTCL patients. This study therefore focused on the immunomodulatory effects of bexarotene in vivo using an EL4 mouse T-cell lymphoma model, followed by investigation in CTCL patients treated with bexarotene. Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment. Based on those results, we then evaluated serum levels of CCL22, CXCL5, and CXCL10 in 25 patients with CTCL, revealing that CCL22 was significantly increased in advanced CTCL compared with early CTCL. Next, we evaluated serum levels of CCL22, CXCL5, and CXCL10 in CTCL patients treated with bexarotene. Serum levels of CCL22 were significantly decreased in 80% of CTCL patients who responded to bexarotene therapy. In addition, immunofluorescence staining revealed CD163+ M2 macrophages as the main source of CCL22. Moreover, bexarotene decreased the production of CCL22 by M2 macrophages generated from monocytes in vitro. Our findings suggest that the clinical benefits of bexarotene are partially attributable to suppressive effects on the production of CCL22 by M2-polarized tumor-associated macrophages.

  48. Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. International-journal Peer-reviewed

    Fujimura T, Sato Y, Tanita K, Lyu C, Kambayashi Y, Amagai R, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Uchi H, Yamamoto Y, Hata H, Funakoshi T, Nonomura Y, Tanaka R, Okuhira H, Wada N, Hashimoto A, Aiba S

    Frontiers in medicine　6　86-86　2019

    DOI： 10.3389/fmed.2019.00086 　

    More details Close

    Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly higher in responders than in non-responders. In contrast, there were no significant differences in baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  49. Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection. Peer-reviewed

    Fujimura T, Kambayashi Y, Sato Y, Tanita K, Amagai R, Hashimoto A, Hidaka T, Aiba S

    Frontiers in medicine　6　140　2019

    DOI： 10.3389/fmed.2019.00140 　

  50. Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. Peer-reviewed

    Kambayashi Y, Fujimura T, Hidaka T, Aiba S

    Frontiers in medicine　6　174　2019

    DOI： 10.3389/fmed.2019.00174 　

  51. Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

    T. Fujimura, Y. Sato, Y. Kambayashi, K. Tanita, A. Tsukada, H. Terui, A. Hashimoto, S. Aiba

    British Journal of Dermatology　179　(6)　1392-1395　2018/12

    DOI： 10.1111/bjd.16676 　

    ISSN： 0007-0963

    eISSN： 1365-2133

  52. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. Peer-reviewed

    Fujimura T, Lyu C, Tsukada A, Sato Y, Kambayashi Y, Aiba S

    The Journal of dermatology　2018/10

    DOI： 10.1111/1346-8138.14684 　

    ISSN： 0385-2407

  53. Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy. Peer-reviewed

    Sato Y, Fujimura T, Kambayashi Y, Tanita K, Tono H, Hashimoto A, Aiba S

    The Journal of dermatology　45　(9)　1105-1108　2018/09

    DOI： 10.1111/1346-8138.14508 　

    ISSN： 0385-2407

  54. Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis. Peer-reviewed

    Amagai R, Fujimura T, Kambayashi Y, Furudate S, Sato Y, Tanita K, Hashimoto A, Aiba S

    Case reports in oncology　11　(3)　671-675　2018/09

    DOI： 10.1159/000493089 　

    ISSN： 1662-6575

  55. HLA-DRB1*04:05 in two cases of Vogt–Koyanagi–Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Kayo Tanita, Yota Sato, Takanori Hidaka, Astushi Otsuka, Hidenori Tanaka, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    Journal of Dermatology　45　(6)　735-737　2018/06/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14273 　

    ISSN： 1346-8138 0385-2407

  56. Pigmented Epithelioid Melanocytoma (Animal Types of Melanoma) on the Nose. Peer-reviewed

    Ohuchi K, Fujimura T, Kambayashi Y, Tono H, Ohtake E, Hashimoto A, Aiba S

    Case reports in oncology　11　(2)　378-382　2018/05

    DOI： 10.1159/000490237 　

  57. Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba

    Journal of Dermatology　45　(4)　e84-e85　2018/04/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14111 　

    ISSN： 1346-8138 0385-2407

  58. Successful control of phototherapy-resistant lymphomatoid papulosis with oral bexarotene Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba

    Journal of Dermatology　45　(2)　e37-e38　2018/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14095 　

    ISSN： 1346-8138 0385-2407

  59. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Erika Tamabuchi, Eika Otake, Hisayuki Tono, Masato Mizuashi, Sadanori Furudate, Setsuya Aiba

    Journal of Dermatology　45　(2)　e35-e36　2018/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14085 　

    ISSN： 1346-8138 0385-2407

  60. Tumor-associated macrophages: Therapeutic targets for skin cancer Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Yasuhiro Fujisawa, Takanori Hidaka, Setsuya Aiba

    Frontiers in Oncology　8　3　2018/01/23

    Publisher: Frontiers Media S.A.

    DOI： 10.3389/fonc.2018.00003 　

    ISSN： 2234-943X

  61. Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　1-5　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000485612 　

    ISSN： 1662-6575

  62. Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Peer-reviewed

    Taku Fujimura, Kayo Tanita, Yota Sato, Yumi Kambayashi, Sadanori Furudate, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　29-32　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000486278 　

    ISSN： 1662-6575

  63. Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Yota Sato, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　114-118　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000487127 　

    ISSN： 1662-6575

  64. Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy Peer-reviewed

    Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　212-215　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000488236 　

    ISSN： 1662-6575

  65. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Yota Sato, Kayo Tanita, Chunbing Lyu, Sadanori Furudate, Setsuya Aiba

    Experimental Dermatology　27　(1)　64-70　2018/01/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/exd.13417 　

    ISSN： 1600-0625 0906-6705

  66. The expression of matrix metalloproteinases in receptor activator of nuclear factor kappa-B ligand (RANKL)-expressing cancer of apocrine origin Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Chunbing Lyu, Takanori Hidaka, Aya Kakizaki, Yota Sato, Kayo Tanita, Setsuya Aiba

    Anticancer Research　38　(1)　113-120　2018/01/01

    Publisher: International Institute of Anticancer Research

    DOI： 10.21873/anticanres.12198 　

    ISSN： 1791-7530 0250-7005

  67. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study Peer-reviewed

    Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

    Oncotarget　9　(21)　15542-15551　2018

    Publisher: Impact Journals LLC

    DOI： 10.18632/oncotarget.24509 　

    ISSN： 1949-2553

  68. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. International-journal Peer-reviewed

    Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S

    Frontiers in oncology　8　530-530　2018

    DOI： 10.3389/fonc.2018.00530 　

    More details Close

    Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  69. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(9)　e226-e227　2017/09

    DOI： 10.1111/1346-8138.13898 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  70. Phase I study of nivolumab combined with IFN-beta for patients with advanced melanoma Peer-reviewed

    Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Hisayuki Tono, Akira Tsukada, Takahiro Haga, Akira Hashimoto, Ryo Morimoto, Takuhiro Yamaguchi, Tadao Takano, Setsuya Aiba

    ONCOTARGET　8　(41)　71181-71187　2017/09

    DOI： 10.18632/oncotarget.17090 　

    ISSN： 1949-2553

    eISSN： 1949-2553

  71. Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Takanori Hidaka, Setsuya Aiba

    ANTICANCER RESEARCH　37　(7)　3461-3471　2017/07

    DOI： 10.21873/anticanres.11714 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  72. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Takanori Hidaka, Yota Sato, Kayo Tanita, Hisayuki Tono, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(5)　592-595　2017/05

    DOI： 10.1111/1346-8138.13707 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  73. Retrospective Investigation of Cutaneous Squamous Cell Carcinoma on the Lip Treated with Peplomycin Administered Through a Superficial Temporal Artery Peer-reviewed

    Taku Fujimura, Kazuhiro Takahashi, Yumi Kambayashi, Sadanori Furudate, Takanori Hidaka, Aya Kakizaki, Akiko Watabe, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ANTICANCER RESEARCH　37　(4)　1885-1889　2017/04

    DOI： 10.21873/anticanres.11526 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  74. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takanori Hidaka, Takahiro Haga, Akira Hashimoto, Ryo Morimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(3)　E13-E14　2017/03

    DOI： 10.1111/1346-8138.13532 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  75. Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways Peer-reviewed

    T. Fujimura, Y. Kambayashi, S. Furudate, A. Kakizaki, T. Hidaka, S. Aiba

    British Journal of Dermatology　176　(2)　387-394　2017/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/bjd.14864 　

    ISSN： 1365-2133 0007-0963

  76. Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yota Sato, Takanori Hidaka, Kayo Tanita, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　52-56　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000455091 　

    ISSN： 1662-6575

  77. Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis Peer-reviewed

    Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Takanori Hidaka, Kayo Tanita, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　106-111　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000456001 　

    ISSN： 1662-6575

  78. Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yota Sato, Takanori Hidaka, Sadanori Furudate, Yumi Kambayashi, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　328-332　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000468981 　

    ISSN： 1662-6575

  79. Sarcoidosis-Lymphoma Syndrome Associated with Folliculotropic Peripheral T Cell Lymphoma Not Otherwise Specified Peer-reviewed

    Saaya Yoshida, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Masato Mizuashi, Setsuya Aiba

    Case Reports in Oncology　10　(1)　372-376　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000472249 　

    ISSN： 1662-6575

  80. Sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　9　(3)　644-649　2016/09/13

    Publisher: S. Karger AG

    DOI： 10.1159/000450974 　

    ISSN： 1662-6575

  81. Multiple metastasized extramammary Paget's disease cured with bisphosphonate risedronate sodium after CyberKnife radiosurgery and docetaxel chemotherapy Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Aya Kakizaki, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    DERMATOLOGICA SINICA　34　(3)　155-157　2016/09

    DOI： 10.1016/j.dsi.2016.02.001 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  82. RANKL expression is a useful marker for differentiation of pagetoid squamous cell carcinoma in situ from extramammary Paget disease Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Sadanori Furudate, Setsuya Aiba

    JOURNAL OF CUTANEOUS PATHOLOGY　43　(9)　772-775　2016/09

    DOI： 10.1111/cup.12743 　

    ISSN： 0303-6987

    eISSN： 1600-0560

  83. Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    JOURNAL OF DERMATOLOGICAL SCIENCE　83　(3)　167-173　2016/09

    DOI： 10.1016/j.jdermsci.2016.05.015 　

    ISSN： 0923-1811

    eISSN： 1873-569X

  84. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Aya Kakizaki, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　43　(6)　686-689　2016/06

    DOI： 10.1111/1346-8138.13229 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  85. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takanori Hidaka, Masayuki Asano, Setsuya Aiba

    EXPERIMENTAL DERMATOLOGY　25　(5)　397-399　2016/05

    DOI： 10.1111/exd.12949 　

    ISSN： 0906-6705

    eISSN： 1600-0625

  86. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Masayuki Asano, Akiko Watabe, Setsuya Aiba

    EXPERIMENTAL DERMATOLOGY　25　(2)　107-112　2016/02

    DOI： 10.1111/exd.12873 　

    ISSN： 0906-6705

    eISSN： 1600-0625

  87. Receptor Activator of NF-kappa B Ligand Promotes the Production of CCL17 from RANK+M2 Macrophages Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Masayuki Asano, Aya Kakizaki, Setsuya Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　(11)　2884-2887　2015/11

    DOI： 10.1038/jid.2015.209 　

    ISSN： 0022-202X

    eISSN： 1523-1747

  88. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. International-journal Peer-reviewed

    Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H, Aiba S

    Oncoimmunology　4　(11)　e1047584　2015/11

    DOI： 10.1080/2162402X.2015.1047584 　

    ISSN： 2162-4011

    More details Close

    An imbalance of immunosuppressive cells and cytotoxic cells plays an important role in the tumor-bearing host. Together with regulatory T cells (Tregs), tumor-associated macrophages (TAMs) play roles in maintaining the tumor microenvironment. Since interferon beta (IFN-β) has been clinically used for the treatment of malignant melanoma, we investigated the immunomodulatory effect of IFN-β during melanoma growth to elucidate the effects of IFN-β on the tumor microenvironment by using the B16F10 melanoma model. Peritumorally administered IFN-β significantly decreased the mRNA expression and production of Th2-related chemokines, which suppressed the recruitment of Tregs in B16F10 melanoma. Since the administration of IFN-β augments the expression of PD-1 on TILs, the co-administration of anti-PD-1 Ab augmented the therapeutic effect of IFN-β for the treatment of B16F10 melanoma. Moreover, in parallel with the mouse model, in the human system, IFN-β decreased the production of Th2-related chemokines and augmented the production of Th1-related chemokines from monocyte-derived M2 macrophages. Since these immunomodulatory effects of IFN-β on macrophages were also observed in the lesional skin of human in-transit melanoma, our present data suggest one of the possible immunomodulatory effects of IFN-β and support the possibility of IFN-β in combination with anti-PD-1 Ab for the treatment of melanoma.

  89. The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Masayuki Asano, Aya Kakizaki, Setsuya Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　(10)　2547-2550　2015/10

    DOI： 10.1038/jid.2015.199 　

    ISSN： 0022-202X

    eISSN： 1523-1747

  90. Merkel cell carcinoma concomitant with invasive Bowen's disease: Immunohistochemical investigation of tumor-infiltrating leukocytes Peer-reviewed

    Hisayuki Tono, Taku Fujimura, Eimei Iwama, Yoshiyuki Kusakari, Sadanori Furudate, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　7　(1)　1-6　2015/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000371732 　

    ISSN： 1662-6567

  91. Immunohistochemical similarities between lichen sclerosus et atrophicus and morphea: A case study Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　7　(1)　39-45　2015/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000381010 　

    ISSN： 1662-6567

  92. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages Peer-reviewed

    Kakizaki Aya, Fujimura Taku, Furudate Sadanori, Kambayashi Yumi, Yamauchi Takeshi, Yagita Hideo, Aiba Setsuya

    ONCOIMMUNOLOGY　4　(11)　2015

    DOI： 10.1080/2162402X.2015.1047584 　

    ISSN： 2162-402X

  93. Comparison of CD163(+) Macrophages and CD206(+) Cells in Lesional Skin of CD30(+) Lymphoproliferative Disorders of Lymphomatoid Papulosis and Primary Cutaneous Anaplastic Large-cell Lymphoma Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Mitsuko Kawano, Kouetsu Ogasawara, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　95　(5)　600-602　2015

    DOI： 10.2340/00015555-2016 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  94. Immunomodulatory Effects of Peplomycin on Immunosuppressive and Cytotoxic Cells in the Lesional Skin of Cutaneous Squamous Cell Carcinoma Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    DERMATOLOGY　230　(3)　250-255　2015

    DOI： 10.1159/000369166 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  95. Isolated collagenoma developing on the scalp Peer-reviewed

    Toshiya Takahashi, Taku Fujimura, Yumi Kambayashi, Yukikazu Numata, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　24　(6)　704-706　2014/12

    DOI： 10.1684/ejd.2014.2445 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  96. メルケル細胞癌におけるエトポシド単剤療法 その免疫学的検討

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　30回　125-125　2014/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  97. Successful treatment of eccrine porocarcinoma metastasized to a cervical lymph node with cyberknife radiosurgery Peer-reviewed

    Taku Fujimura, Akira Hashimoto, Sadanori Furudate, Yumi Kambayashi, Takahiro Haga, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　159-163　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000365348 　

    ISSN： 1662-6567

  98. Keratoacanthoma accompanied by multiple lung squamous cell carcinomas developing in a renal transplant recipient Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　169-175　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000365626 　

    ISSN： 1662-6567

  99. A possible mechanism in the recruitment of eosinophils and Th2 cells through CD163(+) M2 macrophages in the lesional skin of eosinophilic cellulitis Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　24　(2)　180-185　2014/03

    DOI： 10.1684/ejd.2014.2283 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  100. Induction of CD163(+) M2 Macrophages in the Lesional Skin of Eosinophilic Pustular Folliculitis Peer-reviewed

    Akiko Hagiwara, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Saori Kagatani, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(1)　104-106　2014

    DOI： 10.2340/00015555-1612 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  101. Generalized Granulomatous Dermatitis Accompanied by Myelodysplastic Syndrome Peer-reviewed

    Akiko Hagiwara, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Yukikazu Numata, Takahiro Haga, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(2)　223-224　2014

    DOI： 10.2340/00015555-1656 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  102. Immunosuppressive and Cytotoxic Cells in Invasive versus Non-invasive Bowen's Disease Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(3)　337-339　2014

    DOI： 10.2340/00015555-1729 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  103. Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Bi-weekly Administration of Pegylated Interferon-alpha Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Mitsuko Kawano, Kouetsu Ogasawara, Akira Tsukada, Erika Tamabuchi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(5)　611-612　2014

    DOI： 10.2340/00015555-1807 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  104. Comparison of CD163+CD206+M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Setsuya Aiba

    DERMATOLOGY　229　(4)　369-378　2014

    DOI： 10.1159/000365946 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  105. Expression of CD39/Entpd1 on granuloma-composing cells and induction of Foxp3-positive regulatory T cells in sarcoidosis Peer-reviewed

    T. Fujimura, Y. Kambayashi, S. Aiba

    CLINICAL AND EXPERIMENTAL DERMATOLOGY　38　(8)　883-889　2013/12

    DOI： 10.1111/ced.12094 　

    ISSN： 0307-6938

    eISSN： 1365-2230

  106. 結節性痒疹におけるM2マクロファージの役割

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 高橋 佐和子, 鈴木 弘実, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　7　(5)　448-448　2013/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  107. 皮膚リンパ腫の進展 インターフェロン療法 臨床的有効性と作用機序の検討

    藤村 卓, 古舘 禎騎, 神林 由美, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    Skin Cancer　28　(2)　139-140　2013/11

    Publisher: (一社)日本皮膚悪性腫瘍学会

    DOI： 10.5227/skincancer.28.139 　

    ISSN： 0915-3535

    eISSN： 1884-3549

  108. Successful treatment of syringotropic CD8+mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Masato Mizuashi, Akiko Watabe, Yumi Kambayashi, Setsuya Aiba

    AUSTRALASIAN JOURNAL OF DERMATOLOGY　54　(4)　E82-E84　2013/11

    DOI： 10.1111/j.1440-0960.2012.00944.x 　

    ISSN： 0004-8380

    eISSN： 1440-0960

  109. Successful local control of cutaneous Merkel cell carcinoma on the eyelid with CyberKnife radiosurgery Peer-reviewed

    Akira Tuskada, Taku Fujimura, Akira Hashimoto, Yumi Kambayashi, Sadanori Furudate, Takahiro Haga, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　725-726　2013/09

    DOI： 10.1684/ejd.2013.2123 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  110. Induction of IL-17 producing cells and FoxP3+regulatory T cells in areas of skin affected by localized pemphigus foliaceus Peer-reviewed

    Gen-ichi Tojo, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Akiko Watabe, Akira Hashimoto, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　711-712　2013/09

    DOI： 10.1684/ejd.2013.2116 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  111. Immunosuppression-associated eosinophilic pustular folliculitis (IS-EPF) developing after Highly Active Anti-Retroviral Therapy (HAART): the possible mechanisms through CD163(+) M2 macrophages Peer-reviewed

    Shuko Okada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Katsuko Kikuchi, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　713-714　2013/09

    DOI： 10.1684/ejd.2013.2117 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  112. Pigmented Necrobiosis Lipoidica Accompanied by Insulin-dependent Diabetes Mellitus Induces CD163(+) Proinflammatory Macrophages and Interleukin-17-producing Cells Peer-reviewed

    Chihiro Wakusawa, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(4)　475-476　2013

    DOI： 10.2340/00015555-1502 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  113. Pigmented epithelioid melanocytoma: Immunohistochemical profiles of tumour-infiltrating histiocytes Peer-reviewed

    Anna Sadayasu, Taku Fujimura, Takahiro Haga, Yumi Kambayashi, Sadanori Furudate, Setsuya Aiba

    Acta Dermato-Venereologica　93　(4)　481-482　2013

    DOI： 10.2340/00015555-1507 　

    ISSN： 0001-5555 1651-2057

  114. Squamous Cell Carcinoma Arising from Keratitis-Ichthyosis-Deafness Syndrome Peer-reviewed

    Hiroshi Mayama, Taku Fujimura, Masayuki Asano, Yumi Kambayashi, Yukikazu Numata, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(5)　583-584　2013

    DOI： 10.2340/00015555-1535 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  115. Comparison of Immunosuppressive and Immunomodulatory Cells in Keratoacanthoma and Cutaneous Squamous Cell Carcinoma Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(6)　663-668　2013

    DOI： 10.2340/00015555-1597 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  116. Eosinophilic cellulitis induced by subcutaneous administration of interferon-β Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Masaya Ishibashi, Takahiro Haga, Setsuya Aiba

    Acta Dermato-Venereologica　93　(6)　755-756　2013

    DOI： 10.2340/00015555-1611 　

    ISSN： 0001-5555 1651-2057

  117. Potential use of bisphosphonates in invasive extramammary paget's disease: An immunohistochemical investigation Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    Clinical and Developmental Immunology　2013　164982　2013

    DOI： 10.1155/2013/164982 　

    ISSN： 1740-2522 1740-2530

  118. Successful treatment of plasmacytosis circumorificialis with topical tacrolimus: Two case reports and an immunohistochemical study Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Masaya Ishibashi, Yumi Kambayashi, Gen-Ichi Tojo, Chihiro Wakusawa, Hiroshi Mayama, Setsuya Aiba

    Case Reports in Dermatology　5　(1)　79-83　2013/01

    DOI： 10.1159/000350184 　

    ISSN： 1662-6567

  119. Profiles of cytotoxic t lymphocytes in cutaneous lymphoid hyperplasia of the face Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　5　(1)　88-92　2013/01

    DOI： 10.1159/000350567 　

    ISSN： 1662-6567

  120. Granulysin-bearing cells in the skin lesions of acute graft-versus-host disease: Possible mechanisms for hypohidrosis in graft-versus-host disease Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　5　(1)　93-98　2013/01

    DOI： 10.1159/000350561 　

    ISSN： 1662-6567

  121. Multiple low-grade fibromyxoid sarcoma on the upper arms with atypical histological presentation Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Yukikazu Numata, Setsuya Aiba

    Case Reports in Dermatology　5　(2)　152-155　2013

    Publisher: S. Karger AG

    DOI： 10.1159/000351791 　

    ISSN： 1662-6567

  122. Comparison of Immunosuppressive and Cytotoxic Cells in Angiosarcoma: Development of a Possible Supportive Therapy for Angiosarcoma Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    DERMATOLOGY　227　(1)　14-20　2013

    DOI： 10.1159/000351316 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  123. Comparison of Interleukin-17-Producing Cells in Different Clinical Types of Alopecia Areata Peer-reviewed

    Genichi Tojo, Taku Fujimura, Mitsuko Kawano, Kouetsu Ogasawara, Yumi Kambayashi, Sadanori Furudate, Masato Mizuashi, Setsuya Aiba

    DERMATOLOGY　227　(1)　78-82　2013

    DOI： 10.1159/000353159 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  124. Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163(+) Arginase 1(+) M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    CLINICAL & DEVELOPMENTAL IMMUNOLOGY　2013　325412　2013

    DOI： 10.1155/2013/325412 　

    ISSN： 1740-2522

    eISSN： 1740-2530

  125. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    ONCOIMMUNOLOGY　1　(8)　1433-1434　2012/11

    DOI： 10.4161/onci.21176 　

    ISSN： 2162-4011

  126. Basal cell carcinoma with spontaneous regression: A case report and immunohistochemical study Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　125-132　2012/05

    DOI： 10.1159/000339621 　

    ISSN： 1662-6567

  127. Successful treatment of granuloma faciale with topical tacrolimus: A case report and immunohistochemical study Peer-reviewed

    Gen-Ichi Tojo, Taku Fujimura, Yumi Kambayashi, Katsuko Kikuchi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　158-162　2012/05

    DOI： 10.1159/000341196 　

    ISSN： 1662-6567

  128. Systemic lupus erythematosus accompanied by psoriasis induces IL-27-producing cells in both affected areas of the skin Peer-reviewed

    Gen-Ichi Tojo, Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　181-185　2012/05

    DOI： 10.1159/000342803 　

    ISSN： 1662-6567

  129. Bullous pemphigoid accompanied by aplastic anemia: The induction of IL-17-producing cells in the affected areas of the skin Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Sadanori Furudate, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　211-214　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343882 　

    ISSN： 1662-6567

  130. Profiles of tumor-infiltrating lymphocytes in a case of trichilemmal carcinoma with spontaneous regression Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yukikazu Numata, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　215-221　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343881 　

    ISSN： 1662-6567

  131. Basosquamous cell carcinoma developing from a renal transplantation recipient Peer-reviewed

    Akira Tsukada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　227-232　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000345095 　

    ISSN： 1662-6567

  132. Cutaneous squamous cell carcinoma developing from recessive dystrophic epidermolysis bullosa: A case report and an immunohistochemical study Peer-reviewed

    Akira Tsukada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Yukikazu Numata, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　197-201　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343082 　

    ISSN： 1662-6567

  133. Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Yumi Kambayashi, Akiko Watabe, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　242-246　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000345377 　

    ISSN： 1662-6567

  134. Successful treatment of MMP-9-expressing angiosarcoma with low-dose docetaxel and bisphosphonate Peer-reviewed

    Masaya Ishibashi, Taku Fujimura, Akira Hashimoto, Takahiro Haga, Kaoru Onami, Akira Tsukada, Yumi Kambayashi, Takanori Hidaka, Sadanori Furudate, Ryoko Shimada, Setsuya Aiba

    Case Reports in Dermatology　4　(1)　5-9　2012/01

    DOI： 10.1159/000335999 　

    ISSN： 1662-6567

  135. CD163(+) Adult Xanthogranuloma Arising from Merkel Cell Carcinoma Treated with Local Radiotherapy Peer-reviewed

    Ryoko Shimada, Taku Fujimura, Yumi Kambayashi, Tomoyuki Ohtani, Mei Nasu, Yukikazu Numata, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　631-632　2012

    DOI： 10.2340/00015555-1356 　

    ISSN： 0001-5555

  136. Extranodal T-cell/Histiocyte-rich Large B-cell Lymphoma Presenting Primarily on the Skin Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　637-639　2012

    DOI： 10.2340/00015555-1435 　

    ISSN： 0001-5555

  137. Comparison of Foxp3(+) Regulatory T cells and CD163(+) Macrophages in Invasive and Non-invasive Extramammary Paget's Disease Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　625-628　2012

    DOI： 10.2340/00015555-1453 　

    ISSN： 0001-5555

  138. 増殖型壊疽性膿皮症の1例

    神林 由美, 佐々木 喜教, 水芦 政人, 浅野 雅之, 芳賀 貴裕, 奥山 隆平, 相場 節也

    臨床皮膚科　65　(11)　853-856　2011/10

    Publisher: (株)医学書院

    DOI： 10.11477/mf.1412103068 　

    ISSN： 0021-4973

  139. Therapy-resistant, spontaneously remitting generalized neutrophilic eccrine hidradenitis in a healthy patient decreases the expression of dermcidin in affected eccrine glands Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Kenshi Yamasaki, Setsuya Aiba

    Case Reports in Dermatology　3　(3)　228-234　2011/09

    DOI： 10.1159/000334737 　

    ISSN： 1662-6567

  140. インスリンデテミル注射部に硬結性の紅斑を呈した1例

    神林 由美, 菊地 克子, 宇根 かおり, 相場 節也

    日本皮膚科学会雑誌　121　(4)　685-689　2011/03

    Publisher: (公社)日本皮膚科学会

    DOI： 10.14924/dermatol.121.685 　

    ISSN： 0021-499X

Show all ︎Show first 5

Misc. 94

  1. モガムリズマブ療法後のエトポシド療法が著効した皮膚T細胞リンパ腫の3例

    大内 謙太郎, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 武田 佳奈, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　129　(9)　1913-1913　2019/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  2. イピリムマブ・低線量放射線併用療法が有効であった抗PD-1抗体抵抗性根治切除不能悪性黒色腫の2例

    天貝 諒, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 橋本 彰, 相場 節也

    西日本皮膚科　81　(3)　250-250　2019/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  3. 衛星病巣を伴った色素性母斑の2例

    山崎 絵美, 菊地 克子, 中嶋 夏磯, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚科学会雑誌　129　(7)　1505-1510　2019/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  4. 下腹部に生じた皮膚原発粘液癌の1例

    千葉 広夢, 塚田 全, 入間田 萌花, 遠野 久幸, 神林 由美, 浅野 雅之, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　129　(6)　1340-1340　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  5. 多巣性線維硬化症の1例

    瀬川 倫子, 水芦 政人, 志藤 光介, 玉渕 恵里佳, 神林 由美, 相場 節也, 城田 祐子

    日本皮膚科学会雑誌　129　(5)　1169-1169　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  6. 進行期悪性黒色腫の抗PD1抗体治療における効果予測システムの開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 日高 高徳, 相場 節也

    日本皮膚科学会雑誌　129　(5)　1176-1176　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  7. 自験例を含めた特発性後天性全身性無汗症に対するステロイドパルス療法の有効性についての検討

    吉田 紗彩, 高橋 隼也, 瀬川 雄一朗, 大竹 映香, 遠野 久幸, 神林 由美, 土山 健一郎, 浅野 雅之, 水芦 政人, 相場 節也

    日本皮膚科学会雑誌　129　(5)　1223-1223　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  8. 右鼻腔悪性黒色腫の術後再発に対してペンブロリズマブが奏効した1例

    入間田 萌花, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　35回　125-125　2019/04

    Publisher: (一社)日本皮膚悪性腫瘍学会

  9. 血清因子による抗PD1抗体治療効果予測法の開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 日高 高徳, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　35回　160-160　2019/04

    Publisher: (一社)日本皮膚悪性腫瘍学会

  10. Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19

    T. Fujimura, K. Tanita, Y. Sato, C. Lyu, Y. Kambayashi, Y. Fujisawa, H. Uchi, Y. Yamamoto, A. Otsuka, K. Yoshino, S. Matsushita, T. Funakoshi, S. Fukushima, H. Hata, A. Hashimoto, S. Aiba

    British Journal of Dermatology　2019

    DOI： 10.1111/bjd.18721 　

    ISSN： 0007-0963

    eISSN： 1365-2133

  11. メルケル細胞癌におけるpSTAT5B発現意義の検討

    佐藤 遥太, 藤村 卓, 古舘 禎騎, 神林 由美, 山本 有紀, 藤本 徳毅, 相場 節也

    西日本皮膚科　80　(3)　275-275　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  12. モガムリズマブ投与後の局所サイバーナイフが著効した毛包向性菌状息肉症の1例

    谷田 佳世, 藤村 卓, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 橋本 彰, 相場 節也

    西日本皮膚科　80　(3)　284-284　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  13. ダブラフェニブ・トラメチニブ療法中に生じた重症多形滲出性紅斑の1例

    神林 由美, 藤村 卓, 水芦 政人, 日高 高徳, 遠野 久幸, 大竹 映香, 玉渕 恵里佳, 中嶋 夏磯, 佐々木 留伊, 相場 節也

    西日本皮膚科　80　(3)　291-291　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  14. モガムリズマブで治療したCCR4陽性菌状息肉症の3例

    谷田 佳世, 藤村 卓, 神林 由美, 佐藤 遥太, 遠野 久幸, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　130-130　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  15. イピリムマブ、イミキモド併用療法が著効を示した悪性黒色腫多発in-transit転移の1例

    大内 謙太郎, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 塚田 全, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　141-141　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  16. 東北大学におけるニボルマブ、ダブラフェニブ・トラメチニブ連続投与が著効した悪性黒色腫の4例

    佐藤 遥太, 藤村 卓, 谷田 佳世, 神林 由美, 塚田 全, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　147-147　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  17. 盲腸癌を合併した浸潤性乳房外パジェット病の1例

    神林 由美, 藤村 卓, 大内 謙太郎, 佐々木 留伊, 大竹 映香, 遠野 久幸, 浅野 雅之, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　176-176　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  18. モガムリズマブ投与後の局所サイバーナイフが著効した毛包向性菌状息肉症の1例

    谷田 佳世, 藤村 卓, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 橋本 彰, 相場 節也

    西日本皮膚科　80　(3)　284-284　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  19. メルケル細胞癌におけるpSTAT5B発現意義の検討

    佐藤 遥太, 藤村 卓, 古舘 禎騎, 神林 由美, 山本 有紀, 藤本 徳毅, 相場 節也

    西日本皮膚科　80　(3)　275-275　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  20. Pigmented Epithelioid Melanocytomaの1例

    大内 謙太郎, 橋本 彰, 浅野 雅之, 土山 健一郎, 神林 由美, 遠野 久幸, 大竹 映香, 佐々木 留伊, 相場 節也

    日本皮膚科学会雑誌　128　(7)　1517-1517　2018/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  21. 免疫チェックポイント阻害薬による免疫関連副作用の予測システムの開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 舩越 建, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1231-1231　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  22. ニボルマブ,ダブラフェニブ+トラメチニブの連続投与によりぶどう膜炎を生じた悪性黒色腫の2例

    谷田 佳世, 藤村 卓, 神林 由美, 武田 佳奈, 遠野 久幸, 佐藤 遥太, 塚田 全, 橋本 彰, 大友 孝昭, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1233-1233　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  23. 非侵襲熱物性計測による皮膚腫瘍の早期診断手法の開発

    佐藤 遥太, 藤村 卓, 岡部 孝裕, 谷田 佳世, 神林 由美, 圓山 重直, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1232-1232　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  24. 非侵襲熱物性計測による悪性黒色腫の早期診断手法の開発

    藤村 卓, 岡部 孝裕, 神林 由美, 佐藤 遥太, 谷田 佳世, 圓山 重直, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　389-389　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  25. 東北大学皮膚科における皮膚T細胞リンパ腫に対するベキサロテン使用経験

    佐藤 遥太, 藤村 卓, 谷田 佳世, 神林 由美, 橋本 彰, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　387-387　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  26. 炭酸ガスレーザー焼灼を行ったHailey-Hailey病の1例

    浅野 雅之, 武田 佳奈, 八丁目 直和, 玉渕 恵里佳, 大竹 映香, 遠野 久幸, 神林 由美, 菊地 克子, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　383-383　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  27. ベキサロテンで寛解維持中のリンパ腫様丘疹症の1例

    武田 佳奈, 藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 谷田 佳世, 佐藤 遥太, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　128　(3)　429-429　2018/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  28. 下腿優位に皮疹が出現したカポジ水痘様発疹症の1例

    中嶋 夏磯, 浅野 雅之, 佐々木 留伊, 大竹 映香, 遠野 久幸, 神林 由美, 山崎 研志, 相場 節也

    日本皮膚科学会雑誌　128　(3)　428-428　2018/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  29. 溶連菌感染後に発症した重症多形滲出性紅斑の1例

    佐々木 留伊, 水芦 政人, 神林 由美, 日高 高徳, 遠野 久幸, 玉渕 恵里佳, 大竹 映香, 谷田 佳世, 中嶋 夏磯, 相場 節也

    日本皮膚科学会雑誌　128　(2)　223-223　2018/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  30. 当科における皮膚T細胞リンパ腫に対するベキサロテン使用経験

    藤村 卓, 谷田 佳世, 佐藤 遥太, 古館 禎騎, 神林 由美, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　128　(1)　60-60　2018/01

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  31. Safety dose and prediction of immune-related adverse event of nivolumab combined with IFN-beta in patients with advanced melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka, K. Tanita, Y. Sato, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(10)　S282-S282　2017/10

    ISSN： 0022-202X

    eISSN： 1523-1747

  32. Immunomodulatory effects of bexarotene on tumor-associated macrophages in patients with mycosis fungoides

    K. Tanita, T. Fujimura, Y. Sato, C. Lyu, Y. Kambayashi, S. Furudate, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(10)　S291-S291　2017/10

    ISSN： 0022-202X

    eISSN： 1523-1747

  33. サルコイド反応を伴う末梢性T細胞リンパ腫の1例

    中嶋 夏磯, 水芦 政人, 佐々木 留伊, 大竹 映香, 遠野 久幸, 日高 高徳, 神林 由美, 岡田 修子, 相場 節也, 市川 聡, 福原 規子, 一迫 玲, 村井 孝弥

    日本皮膚科学会雑誌　127　(10)　2341-2341　2017/09

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  34. 血管肉腫との鑑別を要したSpindle Cell Hemangiomaの1例

    遠野 久幸, 塚田 全, 神林 由美, 日高 高徳, 大竹 映香, 水芦 政人, 菊地 克子, 相場 節也, 富田 靖

    日本皮膚科学会雑誌　127　(7)　1560-1560　2017/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  35. Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(5)　S48-S48　2017/05

    ISSN： 0022-202X

    eISSN： 1523-1747

  36. ベキサロテンが著効した魚鱗癬様皮疹を呈する皮膚末梢T細胞リンパ腫の1例

    谷田 佳世, 藤村 卓, 遠野 久幸, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1151-1151　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  37. ベムラフェニブ・ラッシュに発症したケラトアカントーマの1例 その免疫学的背景の検討

    佐藤 遥太, 藤村 卓, 谷田 佳世, 古舘 禎騎, 神林 由美, 日高 高徳, 遠野 久幸, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1142-1142　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  38. 東北大学で施行した進行期悪性黒色腫に対するイピリムマブ投与7症例の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 塚田 全, 遠野 久幸, 日高 高徳, 佐藤 遥太, 谷田 佳世, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1140-1140　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  39. BRAF阻害剤により角化性結節と掌蹠角化症が出現しBRAF/MEK阻害剤変更後に消退傾向を示した悪性黒色腫の1例

    古舘 禎騎, 藤村 卓, 遠野 久幸, 玉渕 めい, 神林 由美, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　163-163　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  40. ダブラフェニブ+トラメチニブ併用療法が著効した悪性黒色腫胆嚢転移の1例

    谷田 佳世, 藤村 卓, 遠野 久幸, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　157-157　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  41. 根治切除不能悪性黒色腫16例に対するニボルマブの使用経験

    藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 塚田 全, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(2)　227-227　2017/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  42. 悪性黒色腫に対する化学療法薬が腫瘍免疫に与える影響

    柿崎 彩, 藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 佐藤 遥太, 谷田 佳世, 相場 節也

    日本皮膚科学会雑誌　127　(2)　210-210　2017/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  43. 膠原病,血管炎に伴う皮膚潰瘍と壊疽性膿皮症 (特集 慢性皮膚潰瘍の治療)

    神林 由美, 相場 節也

    Pepars　(119)　20-26　2016/11

    Publisher: 全日本病院出版会

    ISSN： 1349-645X

  44. アセトアミノフェンによる中毒性表皮壊死症に対して血漿交換療法を含む集学的治療が奏功した1例

    島 久登, 山本 多恵, 秋保 真穂, 吉田 舞, 藤倉 恵美, 神林 由美, 水芦 政人, 阿部 俊宏, 小林 淳, 小松 亜紀, 佐々木 俊一, 宮崎 真理子, 伊藤 貞嘉

    日本アフェレシス学会雑誌　35　(Suppl.)　166-166　2016/11

    Publisher: (一社)日本アフェレシス学会

    ISSN： 1340-5888

  45. 全身性強皮症に合併した難治性皮膚潰瘍の1例

    谷田 佳世, 神林 由美, 大竹 映香, 福井 玲矛, 山崎 絵美, 遠野 久幸, 西宮 愛望, 滝田 彰子, 玉渕 めい, 土山 健一郎, 浅野 雅之, 水芦 政人, 芳賀 貴裕, 橋本 彰, 相場 節也, 石井 智徳, 田島 つかさ, 山内 正憲

    日本皮膚科学会雑誌　126　(12)　2300-2300　2016/11

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  46. 頭部瘢痕性脱毛に有棘細胞癌を多発した若年性皮膚筋炎の一例

    佐藤 遥太, 神林 由美, 塚田 全, 藤村 卓, 芳賀 貴裕, 菊地 克子, 相場 節也, 萩野谷 和裕

    Journal of Environmental Dermatology and Cutaneous Allergology　10　(4)　460-460　2016/10

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  47. IFN-beta augments the anti-tumor effects of PD-1 Abs in melanoma: the possible immunotherapy for metastatic melanoma

    A. Kakizaki, T. Fujimura, S. Furudate, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　136　(9)　S238-S238　2016/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  48. ニボルマブ、イピリムマブ連続投与が著効した転移性悪性黒色腫の1例

    古舘 禎騎, 藤村 卓, 神林 由美, 日高 高徳, 遠野 久幸, 塚田 全, 浅野 雅之, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　126　(9)　1728-1728　2016/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  49. 副作用のためST合剤を継続できず、ミノサイクリンで治療した皮膚リンパ管型ノカルジア症の1例

    西宮 愛望, 神林 由美, 滝田 彰子, 鈴木 弘実, 菊地 克子, 相場 節也, 具 芳明, 豊川 真弘

    日本皮膚科学会雑誌　126　(7)　1321-1322　2016/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  50. 乳房外パジェット病における免疫寛容のメカニズム

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 日高 高徳, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　139-139　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  51. 菌状息肉症における腫瘍随伴性マクロファージの役割

    古舘 禎騎, 藤村 卓, 柿崎 彩, 神林 由美, 浅野 雅之, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　130-130　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  52. 悪性黒色腫に対する抗PD-1抗体、IFN-β併用療法の可能性

    柿崎 彩, 藤村 卓, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　120-120　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  53. 汗過敏型コリン性蕁麻疹の1例

    滝田 彰子, 神林 由美, 西宮 愛望, 山崎 研志, 相場 節也

    日本皮膚科学会雑誌　126　(5)　1000-1000　2016/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  54. 皮膚悪性腫瘍を疑った顔面の放線菌症の1例

    西宮 愛望, 神林 由美, 滝田 彰子, 二瓶 順子, 相場 節也, 具 芳明

    日本皮膚科学会雑誌　126　(2)　168-168　2016/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  55. 足底の皮膚腫瘍切除後に人工真皮を用いた場合、どのような再建が望ましいのか

    芳賀 貴裕, 神林 由美, 土山 健一郎, 吉田 紗彩, 玉渕 恵里佳, 西宮 愛望, 相場 節也

    Skin Surgery　25　(1)　49-49　2016/02

    Publisher: 日本臨床皮膚外科学会

    ISSN： 0918-9688

  56. 表皮細胞におけるpSTAT染色パターンからみる炎症性皮膚疾患

    神林 由美, 藤村 卓, 浅野 雅之, 柿崎 彩, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　9　(5)　471-471　2015/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  57. Topical administration of imiquimod modifies the profiles of tumor-associated macrophages in B16F10 melanomas.

    T. Fujimura, S. Furudate, Y. Kambayashi, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　S22-S22　2015/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  58. Tumor-associated macrophages and stromal factors play roles in developing mycosis fungoides in the different stages

    S. Furudate, T. Fujimura, A. Kakizaki, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　S78-S78　2015/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  59. 乳房外パジェット病治療における抗RANKL抗体製剤の可能性

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　31回　154-154　2015/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  60. 根治切除不能悪性黒色腫8例に対する抗PD-1抗体の使用経験

    藤村 卓, 古舘 禎騎, 神林 由美, 志藤 光介, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　31回　144-144　2015/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  61. 当科における複数の皮膚悪性腫瘍を併発した7例のまとめ

    石原 志乃, 芳賀 貴裕, 玉渕 恵里佳, 神林 由美, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1441-1441　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  62. 加水分解小麦含有石鹸で感作されアナフィラキシー症状を発症した小麦アレルギーの2例

    塚田 全, 岡田 修子, 神林 由美, 芳賀 貴裕, 山崎 研志, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1431-1431　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  63. BRAF V600E遺伝子変異を認めたmulti-spotted malignant melanoma in situの1例

    岩間 英明, 藤村 卓, 高橋 隼也, 古舘 禎騎, 神林 由美, 柿崎 彩, 草刈 良之, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　125　(4)　941-941　2015/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  64. Isolated collagenomaの1例とその免疫組織学的所見

    高橋 隼也, 藤村 卓, 神林 由美, 沼田 透効, 相場 節也

    日本皮膚科学会雑誌　125　(4)　928-928　2015/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  65. CD30+ lymphoporliferative disorderにおける腫瘍内浸潤マクロファージの検討

    藤村 卓, 柿崎 彩, 古舘 禎騎, 神林 由美, 相場 節也

    皮膚の科学　14　(1)　45-45　2015/02

    Publisher: 日本皮膚科学会-大阪地方会・京滋地方会

    ISSN： 1347-1813

    eISSN： 1883-9614

  66. Receptor activator of nuclear factor kappa-B ligand (RANKL) promotes the recruitment of regulatory T cells (Tregs) through M2 macrophages in extramammary Paget's disease

    Y. Kambayashi, T. Fujimura, S. Furudate, M. Asano, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S74-S74　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  67. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages

    T. Fujimura, Y. Kambayashi, S. Furudate, A. Kakizaki, M. Asano, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S74-S74　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  68. CD163(+)CD206(+)Arginase 1(+) M2 macrophages in mycosis fungoides aquired immunostimulatory function by interferon alpha2a

    S. Furudate, T. Fujimura, Y. Kambayashi, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S71-S71　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  69. 円形脱毛症各種病型におけるIL-17産生細胞比率の検討

    古舘 禎騎, 藤村 卓, 東條 玄一, 神林 由美, 水芦 政人, 相場 節也

    日本皮膚科学会雑誌　124　(9)　1783-1784　2014/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  70. 悪性黒色腫in-transit転移に対するIFN-β療法 その免疫学的意義

    藤村 卓, 柿崎 彩, 古舘 禎騎, 神林 由美, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　30回　123-123　2014/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  71. 血管肉腫 その免疫学的背景の検討

    柿崎 彩, 藤村 卓, 神林 由美, 古舘 禎騎, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    西日本皮膚科　76　(3)　291-291　2014/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  72. 水疱性類天疱瘡におけるCD163陽性M2マクロファージの検討

    古舘 禎騎, 藤村 卓, 神林 由美, 柿崎 彩, 相場 節也

    西日本皮膚科　76　(3)　276-276　2014/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  73. PEG-IFNα2a(ペガシス)皮下注で著明な改善を認めたランゲルハンス細胞組織球症の1例

    古舘 禎騎, 藤村 卓, 神林 由美, 玉渕 恵里佳, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　124　(2)　207-208　2014/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  74. 陰嚢部および両下腿に生じた硬化性脂肪肉芽腫の1例

    柿崎 彩, 藤村 卓, 高橋 佐和子, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚科学会雑誌　124　(2)　203-203　2014/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  75. 水疱性類天疱瘡におけるCD163陽性M2マクロファージの検討

    柿崎 彩, 藤村 卓, 古館 禎騎, 神林 由美, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　7　(5)　475-475　2013/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  76. 血管肉腫 その免疫学的検討と新規治療法の開発

    柿崎 彩, 藤村 卓, 神林 由美, 古舘 禎騎, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　127-127　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  77. Bowen病における病期進行と免疫担当細胞の関連の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　116-116　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  78. 皮膚リンパ腫の進展 インターフェロン療法 臨床的有効性と作用機序の検討

    藤村 卓, 古舘 禎騎, 神林 由美, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　64-64　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  79. 再生不良性貧血に合併した水疱性類天疱瘡の1例

    古舘 禎騎, 藤村 卓, 柿崎 彩, 神林 由美, 塚田 全, 沼田 透効, 相場 節也

    西日本皮膚科　75　(3)　272-272　2013/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  80. Imiquimod with dacarbazine diferentiates B7H1-expressing MDSC into IFN-gamma producing macrophages in B16F10 melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, N. Ishii, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　133　S3-S3　2013/05

    ISSN： 0022-202X

  81. Comparison of immunosuppressive cells and cytoloxic cells in cutaneous angiosarcoma: The development of novel supportive therapy for cutaneous angiosarcoma

    Y. Kambayashi, T. Fujimura, S. Furudate, Y. Kimura, A. Hashimoto, T. Haga, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　133　S168-S168　2013/05

    ISSN： 0022-202X

  82. 皮膚偽リンパ腫および頭部皮膚B細胞リンパ腫における細胞傷害性T細胞の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　123　(5)　983-983　2013/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  83. 先天性表皮水疱症より発症した有棘細胞癌 自己水疱蓋グラフト、パンチグラフトの有用性の検討

    塚田 全, 藤村 卓, 古舘 禎騎, 神林 由美, 沼田 透効, 渡部 晶子, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　123　(5)　974-974　2013/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  84. Imiquimod augments the expression of B7H1 on CD11b+Gr1+myeloid derived suppressor cells (MDSCs) in B16F10 melanoma

    T. Fujimura, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　132　S127-S127　2012/09

    ISSN： 0022-202X

  85. Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and cutaneous squamous cell carcinoma

    Y. Kambayashi, T. Fujimura, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　132　S40-S40　2012/09

    ISSN： 0022-202X

  86. 多形紅斑様の皮疹を呈したクロムによる接触皮膚炎の1例

    塚田 全, 菊地 克子, 神林 由美, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　6　(3)　302-302　2012/07

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  87. T-cell/Histiocyte-Rich B-Cell Lymphoma (THRLBCL) primarily presenting on the skin: a case report and immunohistochemical study

    Yumi Kambayashi, Taku Fujimura, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　39　96-96　2012/06

    ISSN： 0385-2407

  88. Cutaneous lymphadenoma: a case report and immunohistochemical study

    Taku Fujimura, Yumi Kambayashi, Takahiro Haga, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　39　88-88　2012/06

    ISSN： 0385-2407

  89. 東北大学病院皮膚科における血管肉腫の治療変遷と予後に関する検討

    芳賀 貴裕, 神林 由美, 塚田 全, 石橋 昌也, 藤村 卓, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　28回　132-132　2012/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  90. 放射線治療後にxanthogranulomaが出現したMerkel細胞癌の1例

    島田 遼子, 藤村 卓, 那須 めい, 沼田 透効, 玉渕 恵里佳, 大谷 朋之, 神林 由美, 芳賀 貴裕, 相場 節也

    日本皮膚科学会雑誌　122　(4)　1235-1235　2012/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  91. 20年来のケロイドに生じたmalignant peripheral nerve sheath tumorの1例

    蔵本 陽子, 神林 由美, 金山 岳夫, 渡辺 みか, 藤島 史喜, 菊地 克子, 大浪 薫, 相場 節也

    日本皮膚科学会雑誌　121　(4)　741-741　2011/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  92. 非典型的な臨床像を呈した汗疹の3例

    神林 由美, 山崎 研志, 菊地 克子, 芳賀 貴裕, 相場 節也

    日本皮膚科学会雑誌　121　(3)　626-626　2011/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  93. キク皮膚炎の1例

    神林 由美, 松村 美樹子, 塚田 全, 大谷 朋之, 橋本 彰, 菊地 克子, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　4　(5)　408-408　2010/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  94. 診断に苦慮した無色素性黒色腫の1例

    芳賀 貴裕, 神林 由美, 島田 遼子, 舛 貴志, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　26回　191-191　2010/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

Show all ︎Show first 5

Presentations 14

  1. ドセタキセル療法で7年間CRを維持している頭部血管肉腫の1例

    神林 由美, 藤村 卓, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　2019/04

  2. ダブラフェニブ・トラメチニブ療法中に生じた重症多形滲出性紅斑の1例

    神林 由美, 藤村 卓, 水芦 政人, 日高 高徳, 遠野 久幸, 大竹 映香, 玉渕 恵里佳, 中嶋 夏磯, 佐々木 留伊, 相場 節也

    西日本皮膚科　2018/06

  3. Lichen planus follicularis tumidusとの鑑別を要した小児のmilia en plaqueの1例

    神林 由美, 相場 節也, 吉田 紗彩, 田畑 伸子

    日本皮膚科学会雑誌　2018/06

  4. 乳房外パジェット病における免疫寛容のメカニズム

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 日高 高徳, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　2016/05

  5. 表皮細胞におけるpSTAT染色パターンからみる炎症性皮膚疾患

    神林 由美, 藤村 卓, 浅野 雅之, 柿崎 彩, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　2015/11

  6. 乳房外パジェット病治療における抗RANKL抗体製剤の可能性

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　2015/07

  7. Livedo vasculopathy様の皮膚潰瘍を合併しTrousseau症候群が疑われた1例

    神林 由美, 柿崎 彩, 相場 節也

    日本皮膚科学会雑誌　2015/03

  8. メルケル細胞癌におけるエトポシド単剤療法 その免疫学的検討

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　2014/07

  9. 末端黒子型黒色腫の合併を疑ったLaugier-Hunzier-Baran症候群の1例

    神林 由美, 藤村 卓, 岡田 修子, 相場 節也

    日本皮膚科学会雑誌　2014/02

  10. 結節性痒疹におけるM2マクロファージの役割

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 高橋 佐和子, 鈴木 弘実, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　2013/11

  11. 有棘細胞癌を疑った象皮病の1例

    神林 由美, 蔵本 陽子, 坂元 和宏, 渋谷 佐和子, 相場 節也

    日本皮膚科学会雑誌　2012/01

  12. キク皮膚炎の1例

    神林 由美, 松村 美樹子, 塚田 全, 大谷 朋之, 橋本 彰, 菊地 克子, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　2010/11

  13. 健康な成人に生じ、外科的治療を要したBlastomycosis-like pyodermaの1例

    神林 由美, 佐々木 喜教, 芳賀 貴裕, 奥山 隆平, 相場 節也

    日本皮膚科学会雑誌　2009/04

  14. スピッツ母斑と鑑別困難で、切除一年後、センチネルリンパ節転移が判明した小児悪性黒色腫の1例

    神林 由美, 佐々木 喜教, 芳賀 貴裕, 水芦 政人, 浅野 雅之, 奥山 隆平, 相場 節也

    日本皮膚科学会雑誌　2009/03

Show all Show first 5

Research Projects 4

  1. PAI-1・免疫チェックポイント相互阻害による新規免疫療法の開発

    神林 由美

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2022/04/01 - 2025/03/31

  2. LL37 might promote local invasion of melanoma by the stimulation of melanoma cells and tumor-associated macrophages

    Kambayashi Yumi

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Early-Career Scientists

    Institution: Tohoku University

    2020/04/01 - 2022/03/31

    More details Close

    LL37 stimulates tumor-associate macrophage (TAMs) to recruit immunosuppressive cells in tumor microenvironment, leading to tumor progression. Since tumor (T) stage is determined by the vertical invasion of tumor cells in melanoma, we hypothesized LL37 expression level might correlate with the T stage in melanoma patients. To determine pro-angiogenetic factors by LL37 stimulation in melanoma, we used B16F10 melanoma model in vivo.We administered CRAMP (mouse LL37). Intra-tumoral administered CRAMP significantly increased the mRNA expression of p19, MMP1a and MMP9 in B16F10 melanoma. To further confirm the induction of pro-angiogenic factors in melanoma, we stimulated A375 and G361 human melanoma cells by LL37 in vitro. The mRNA expression of p19 and MMP9, but not MMP1, was significantly increased by the stimulation of LL37. Correctively, these results suggested that LL37 stimulates both tumor cells and TAMs to promote the invasion of melanoma by the induction of pro-angiogenic factors.

  3. Development of novel immune therapy for melanoma by targeting tumor associated macrophages

    Fujimura Taku

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2016/04/01 - 2019/03/31

    More details Close

    We have developed several novel systems for tumor immunology fields, especially in the areas of tumor associated macrophages. During this period, we have published 15 research studies about tumor associated macrophages. Among them, we have determined safety dose of IFN-beta in combination with anti-PD1 antibodies, which is based on the logics of tumor associated macrophages. Moreover, we also found the release of sCD163 and CXCL5 from tumor associated macrophages, which could be the biomarker for the prediction of the efficacy of anti-PD1 antibodies for the treatment of advanced, unresectable melanoma patients. Furthermore, we found that these biomarkers are also useful for the prediction of immune related adverse events in patients with melanoma who treated with anti-PD1 antibodies. According to these results, today, we have set up a clinical research for the development of optimal immune therapy using anti-PD1 antibody.

  4. Possible mechanisms of induction of immunotolerance in appocrine-origin skin tumors

    Kambayashi Yumi

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Young Scientists (B)

    Institution: Tohoku University

    2016/04/01 - 2018/03/31

    More details Close

    During this research period, we investigated the immunomodulatory effects of cancer stromal factors on tumor-associated macrophages (TAMs), especially focused on RANKL. For example, we have published the immunomodulatory effects of RANKL on M2 macrophages using DNA macroarray analysis, suggesting that RANKL increases the characteristic chemokines, which could be related with immunosuppressive immune cells such as regulatory T cells. We have published these results on Experimental Dermaotology at 2016. In addition, we found that not only M2 macrophages, but also Langerhans cells in the lesional skin of Extramammary Paget’s disease expresses RANK, leading to produce CCL17 by the stimulation of soluble RANKL. We have published these results on Brit J Dermatol at 2017. In aggregate, we have published 11 research papers, all of which possesses impact factor, during our research period.